Biotech Investors: Chiasma Was Just Called One Of The Most 'Compelling Fresh Ideas' In Pharma

By: via Benzinga
In a report published Monday, Barclays analyst Douglas D. Tsao initiated coverage of Chiasma Inc (NASDAQ: CHMA) with an Overweight ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.